NCT07177534

Brief Summary

Female fertility may be affected by uterine fibroids, although this association has not been elucidated. Our retrospective study has already constructed a predictive model for infertility risk in patients with uterine fibroids using machine learning. We will now validate and optimize this model through a prospective study

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
7,084

participants targeted

Target at P75+ for all trials

Timeline
66mo left

Started Sep 2025

Longer than P75 for all trials

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress10%
Sep 2025Sep 2031

First Submitted

Initial submission to the registry

August 19, 2025

Completed
29 days until next milestone

First Posted

Study publicly available on registry

September 17, 2025

Completed
13 days until next milestone

Study Start

First participant enrolled

September 30, 2025

Completed
6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 30, 2031

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 30, 2031

Last Updated

September 17, 2025

Status Verified

September 1, 2025

Enrollment Period

6 years

First QC Date

August 19, 2025

Last Update Submit

September 16, 2025

Conditions

Keywords

Uterine fibroidsFemale InfertilityPregnancy rate

Outcome Measures

Primary Outcomes (1)

  • The pregnancy rate of women with uterine fibroids.

    Fibroid types range from 0 to 8 according to the FIGO classification. The pregnancy rate varies with different types and size of fibroids. Subserosal fibroids do not exert any detrimental effects on fertility outcomes. Submucosal fibroids have negatively impact fertility. The effect of intramural fibroids on reproductive outcome has been a subject of debate in the past, but recent literature indicates that intramural myomas also negative impact fertility.The pregnancy rate among patients with uterine fibroids is calculated as the proportion of those who achieve pregnancy relative to the total number of patients with uterine fibroids.

    through study completion, an average of 5 years

Secondary Outcomes (6)

  • The rate of spontaneous abortion of women with uterine fibroids.

    through study completion, an average of 5 years

  • The rate of preterm birth of women with uterine fibroids.

    through study completion, an average of 5 years

  • The rate of cesarean section of women with uterine fibroids.

    through study completion, an average of 5 years

  • The rate of placental abruption of women with uterine fibroids.

    through study completion, an average of 5 years

  • The rate of postpartum hemorrhage of women with uterine fibroids.

    through study completion, an average of 5 years

  • +1 more secondary outcomes

Study Arms (2)

UFs with infertile patients

Uterine fibroids combined with infertile women

Other: No intervention

UFs with non-infertile patients

Uterine fibroids combined with non-infertile women

Other: No intervention

Interventions

This study is a retrospective observational study without intervention.

UFs with infertile patientsUFs with non-infertile patients

Eligibility Criteria

Age20 Years - 50 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64)
Sampling MethodNon-Probability Sample
Study Population

Female patients with uterine fibroids

You may qualify if:

  • Women aged 20-50 years with recent desires for conception. Diagnosed with uterine fibroids via ultrasound or pathology. Complete clinical records available. Ability to provide informed consent.

You may not qualify if:

  • Active severe infectious or rheumatologic autoimmune diseases. History of malignant tumors. Incomplete clinical records. Unable to contact via phone or refusal to participate in follow-up.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

LeiomyomaInfertility, Female

Condition Hierarchy (Ancestors)

Neoplasms, Muscle TissueNeoplasms, Connective and Soft TissueNeoplasms by Histologic TypeNeoplasmsGenital Diseases, FemaleFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesGenital DiseasesInfertility

Central Study Contacts

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Target Duration
5 Years
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

August 19, 2025

First Posted

September 17, 2025

Study Start

September 30, 2025

Primary Completion (Estimated)

September 30, 2031

Study Completion (Estimated)

September 30, 2031

Last Updated

September 17, 2025

Record last verified: 2025-09